Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Poland
Clinical trial register · European Union · CTIS

Clinical Trials in Poland, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2556 most recently authorised of 12893 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Nov 2026, 03:17 UTC
2556
Shown in this register
most recently authorised
12,893
Total on CTIS
full historical archive
785
Phase III
within the shown window
Top member states
Spain 1069 France 921 Germany 906 Italy 769 Poland 620 Netherlands 547

Trials with a site in Poland

620 of 2556 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
Faron Pharmaceuticals Oy
Hemic and Lymphatic Diseases
Finland, France, Czechia, Poland
13/11/2026
Phase III
Rapport Therapeutics Inc.
Nervous System Diseases
Netherlands, Austria, Czechia, Belgium, Slovakia, Finland, Poland, Spain, Ireland, Sweden, Germany, Hungary, Denmark, Italy, Portugal
11/11/2026
Phase III
Merck Sharp & Dohme LLC
Eye Diseases
Portugal, Austria, Spain, Czechia, Hungary, France, Poland
11/11/2026
Phase III
Seismic Pharmaceuticals Operations LLC
Cardiovascular Diseases
Spain, Portugal, Bulgaria, Italy, Poland, Romania, Czechia, Greece
10/11/2026
Phase III
Vanda Pharmaceuticals Inc.
Digestive System Diseases
Czechia, Estonia, Bulgaria, Romania, Latvia, Poland
10/11/2026
Phase III
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Germany, Hungary, Poland, Greece, Portugal, Sweden, Spain
10/11/2026
Phase II
UCB Biopharma
Respiratory Tract Diseases
Poland, Ireland, Belgium, Portugal, Italy, France, Spain, Bulgaria, Germany
10/11/2026
Phase III
Novartis Pharma AG
Neoplasms
Czechia, Portugal, Germany, Austria, Poland, Belgium, Spain, Netherlands, Italy, France, Slovakia
10/11/2026
Phase III
Glaxosmithkline Research & Development Limited
Male Urogenital Diseases
Germany, Spain, Italy, France, Netherlands, Poland
10/11/2026
Phase III
Centessa Pharmaceuticals UK Limited
Nervous System Diseases
Italy, Spain, Germany, Finland, Belgium, France, Poland, Austria
09/11/2026
Phase III
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Hungary, Ireland, Germany, Spain, Romania, Denmark, Poland, France, Italy
09/11/2026
Phase II
UCB Biopharma
Respiratory Tract Diseases
Italy, Netherlands, Poland, Belgium, Spain, France, Czechia, Bulgaria, Germany, Slovakia
09/11/2026
Phase III
Priovant Therapeutics Inc.
Skin and Connective Tissue Diseases
Belgium, Czechia, Poland, Netherlands, France, Italy, Spain, Hungary, Germany
06/11/2026
Phase II
Contera Pharma A/S
Nervous System Diseases
Poland, Italy, Spain
05/11/2026
Phase III
Hunan Mabgeek Biotech Co. Ltd.
Skin and Connective Tissue Diseases
Czechia, Spain, Poland
04/11/2026
Phase III
Nektar Therapeutics
Skin and Connective Tissue Diseases
Lithuania, Slovakia, Bulgaria, Greece, Czechia, Poland, Spain, Belgium, Germany
03/11/2026
Phase III
Nektar Therapeutics
Immune System Diseases
Portugal, Austria, Poland, Latvia, Italy, Czechia, Germany, Hungary, Croatia
03/11/2026
Phase II
Novartis Pharma AG
Immune System Diseases
Italy, Netherlands, Poland, Germany, Spain, France
02/11/2026
Phase I
Polpharma Biologics International AG
Nervous System Diseases
Poland, Croatia, Czechia, Bulgaria
02/11/2026
Phase I
Eli Lilly & Co.
Neoplasms
Italy, France, Denmark, Poland, Spain, Germany
02/11/2026
Phase III
Lumos Pharma LLC
Hormonal diseases
Romania, Poland, Italy, France, Spain
30/10/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Nervous System Diseases
Hungary, Belgium, Lithuania, Spain, France, Germany, Netherlands, Poland, Denmark, Slovakia, Italy, Austria, Bulgaria, Portugal, Greece, Czechia, Sweden
30/10/2026
Phase II
Bicara Therapeutics Inc.
Neoplasms
Netherlands, Spain, France, Italy, Belgium, Poland, Germany
30/10/2026
Phase I
Argenx
Musculoskeletal Diseases
Slovenia, Latvia, Denmark, Germany, Belgium, Norway, Spain, Poland, Lithuania, Italy, France, Netherlands
27/10/2026
Phase III
Glaxosmithkline Research & Development Limited
Neoplasms
Czechia, Poland, Austria, Italy, Spain, Sweden, Germany, France, Netherlands, Portugal, Finland, Greece
27/10/2026
Phase I
Merck Healthcare KGaA
Skin and Connective Tissue Diseases
Poland, Germany
27/10/2026
Phase II
Agomab Spain S.L.U.
Respiratory Tract Diseases
Poland, France, Belgium, Italy, Spain, Portugal, Netherlands, Germany
27/10/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Czechia, Germany, Poland
27/10/2026
Phase III
Celcuity Inc.
Neoplasms
Finland, Bulgaria, Portugal, Germany, Greece, Romania, Poland, Hungary, Czechia, Italy, Denmark, Belgium, France, Spain
27/10/2026
Phase II
F. Hoffmann-La Roche AG
Nervous System Diseases
Spain, Belgium, Denmark, France, Poland, Italy, Germany, Ireland
27/10/2026
Phase I/II
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Germany, Spain, France, Poland, Belgium, Netherlands
26/10/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Poland, Romania, Slovakia
26/10/2026
Phase III
Ohb Pediatrics Limited
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Poland, Germany, Netherlands, Italy
23/10/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Portugal, Bulgaria, Germany, Croatia, Hungary, Czechia, Romania, Spain, Italy, Denmark, Slovakia, Greece, Poland
23/10/2026
Phase III
Novartis Pharma AG
Immune System Diseases
Germany, Austria, Poland, Spain, Italy, France
23/10/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Croatia, Spain, Portugal, Hungary, Bulgaria, Poland
21/10/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Respiratory Tract Diseases
Belgium, France, Netherlands, Finland, Italy, Spain, Germany, Poland, Austria
21/10/2026
Phase II
F. Hoffmann-La Roche AG
Nervous System Diseases
Germany, Italy, Netherlands, Poland, France, Ireland, Spain, Austria
21/10/2026
Phase I/II
Camp4 Therapeutics Corp.
Nervous System Diseases
France, Spain, Italy, Netherlands, Poland, Germany
20/10/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Romania, Bulgaria, Poland, Denmark, Spain
20/10/2026
Phase III
AstraZeneca AB
Musculoskeletal Diseases
Netherlands, Belgium, Bulgaria, Romania, Italy, Germany, Austria, Spain, Portugal, Greece, Czechia, Poland, France
20/10/2026
Phase III
Newave Pharmaceutical Inc.
Hemic and Lymphatic Diseases
Poland, Germany, Spain, Czechia, Italy, France
20/10/2026
Phase II
Supernus Pharmaceuticals Inc.
Nervous System Diseases
Poland, Bulgaria, Hungary
20/10/2026
Phase III
Glaxosmithkline Research & Development Limited
Immune System Diseases
France, Belgium, Italy, Spain, Austria, Germany, Netherlands, Portugal, Poland, Greece
19/10/2026
Phase III
Novo Nordisk A/S
Hemic and Lymphatic Diseases
France, Italy, Greece, Poland, Spain, Denmark, Germany
19/10/2026
Phase III
AstraZeneca AB
Cardiovascular Diseases
France, Germany, Austria, Poland, Romania, Italy, Greece, Bulgaria, Spain
19/10/2026
Phase III
Janssen Cilag International
Immune System Diseases
Hungary, Spain, Germany, Poland
15/10/2026
Phase II
Novartis Pharma AG
Immune System Diseases
Portugal, Bulgaria, Belgium, Spain, Denmark, France, Slovakia, Poland, Hungary, Italy, Netherlands, Germany, Austria
15/10/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Spain, Poland, France, Italy, Germany, Czechia, Romania, Hungary
15/10/2026
Phase I
A Study of ARC-02 in B-cell NHL
2026-525606-35-00B-cell Non Hodgkins Lymphoma (NHL)
Taiho Oncology Inc.
Neoplasms
Spain, Poland, France, Italy
13/10/2026
Phase III
Glaxosmithkline Research & Development Limited
Nutritional and Metabolic Diseases
Netherlands, Germany, Austria, France, Spain, Italy, Bulgaria, Poland, Belgium, Greece
13/10/2026
Phase II
Glaxosmithkline Research & Development Limited
Digestive System Diseases
Spain, Denmark, Italy, Poland, France, Germany, Greece
12/10/2026
Phase III
Ferrer Internacional S.A., Prilenia Therapeutics B.V.
Nervous System Diseases
Spain, Italy, Portugal, Poland, France, Netherlands, Germany, Belgium, Czechia
12/10/2026
Phase III
Glaxosmithkline Research & Development Limited
Nutritional and Metabolic Diseases
Netherlands, Greece, Austria, Spain, Italy, France, Belgium, Bulgaria, Germany, Poland
12/10/2026
Phase II
Almirall S.A.
Immune System Diseases
Poland, Spain, Hungary, Bulgaria
09/10/2026
Phase II
Ns Pharma Inc.
Respiratory Tract Diseases
France, Germany, Poland, Italy, Belgium, Spain, Greece
08/10/2026
Phase III
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
Italy, Austria, Greece, Ireland, Bulgaria, Poland, Sweden, Belgium, Germany, Spain, Czechia, France, Romania, Hungary
08/10/2026
Phase III
AstraZeneca AB
Nutritional and Metabolic Diseases
Italy, Czechia, Germany, Bulgaria, France, Poland
08/10/2026
Phase III
Vor Biopharma Inc.
Immune System Diseases
Poland, Spain, Hungary, Italy, Netherlands, Romania, Belgium, France, Bulgaria, Germany
06/10/2026
Phase III
Harmony Biosciences Management Inc.
Nervous System Diseases
France, Germany, Belgium, Spain, Italy, Poland
06/10/2026
Phase III
Vivus B.V., Vivus LLC
Respiratory Tract Diseases
Italy, France, Czechia, Poland, Latvia, Germany, Spain
05/10/2026
Phase III
AstraZeneca AB
Nutritional and Metabolic Diseases
Spain, Poland, Slovakia, Germany
05/10/2026
Phase II
Argenx
Not possible to specify
Spain, Poland, Czechia, Belgium, Italy
05/10/2026
Phase III
Zydus Therapeutics Inc.
Digestive System Diseases
Ireland, Greece, Estonia, Netherlands, Bulgaria, Slovakia, Poland, Latvia, Croatia, Spain, France, Italy
05/10/2026
Phase III
Novartis Pharma AG
Immune System Diseases
Austria, Portugal, Slovakia, Italy, Poland, Hungary, Spain, Czechia, France, Netherlands, Germany
05/10/2026
Phase I/II
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Poland, France, Belgium, Germany, Netherlands, Spain
05/10/2026
Phase III
Pfizer Inc.
Respiratory Tract Diseases
Spain, Poland
01/10/2026
Phase I
Flik Therapeutics Inc.
Nervous System Diseases
Poland
01/10/2026
Phase III
Regeneron Pharmaceuticals Inc.
Nutritional and Metabolic Diseases
Romania, Poland, Hungary, Germany, Spain
29/09/2026
Phase III
Insmed Inc.
Cardiovascular Diseases
Germany, Hungary, Belgium, France, Italy, Sweden, Austria, Poland, Lithuania, Spain, Romania, Greece
29/09/2026
Phase III
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Portugal, Germany, Italy, Czechia, Austria, Spain, Belgium, Netherlands, Poland, Sweden, Greece, Latvia, Hungary, Bulgaria, Romania
29/09/2026
Phase III
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Spain, Bulgaria, Hungary, Poland, Romania, Sweden, Germany, Italy, Latvia, Netherlands, Portugal
29/09/2026
Phase II
Expedition Therapeutics Inc.
Respiratory Tract Diseases
Italy, Germany, Spain, Poland, Czechia, Romania, Hungary, Denmark, Bulgaria
29/09/2026
Phase III
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Spain, Slovakia, Hungary, Czechia, Romania, Estonia, Austria, France, Belgium, Sweden, Italy, Latvia, Poland, Bulgaria, Greece, Germany, Denmark, Lithuania, Netherlands
29/09/2026
Phase III
Crinetics Pharmaceuticals Inc.
Not possible to specify
Sweden, Austria, Spain, Poland, Netherlands, Italy, Germany, France
28/09/2026
Phase III
Kardigan Inc.
Cardiovascular Diseases
Poland, Sweden, Belgium, France, Spain, Hungary, Denmark, Italy, Netherlands
28/09/2026
Phase III
Dianthus Therapeutics Inc.
Immune System Diseases
Czechia, Portugal, Austria, Bulgaria, Germany, France, Latvia, Poland, Italy, Spain, Denmark
28/09/2026
Phase III
AstraZeneca AB
Neoplasms
Italy, Poland, Spain, France, Germany
23/09/2026
Phase III
Almirall S.A.
Skin and Connective Tissue Diseases
Poland, Germany, Portugal, France, Spain, Denmark
22/09/2026
Phase II
Agomab Spain S.L.U.
Digestive System Diseases
France, Germany, Poland, Spain, Czechia, Denmark, Austria, Italy, Belgium, Netherlands
21/09/2026
Phase III
Amgen Inc.
Nutritional and Metabolic Diseases
Czechia, Spain, Poland, Denmark, Germany, Italy, Belgium, Finland
21/09/2026
Phase III
Amgen Inc.
Nutritional and Metabolic Diseases
Germany, Hungary, Czechia, Italy, Poland, Bulgaria
21/09/2026
Phase III
Glaxosmithkline Research & Development Limited
Neoplasms
Denmark, Netherlands, Italy, Spain, France, Portugal, Greece, Poland, Germany, Belgium, Norway, Czechia
21/09/2026
Phase II
AnaCardio AB
Cardiovascular Diseases
Czechia, Slovakia, Spain, Bulgaria, Netherlands, Italy, Poland, Germany, Sweden, Hungary
21/09/2026
Phase III
Celea Therapeutics Inc.
Respiratory Tract Diseases
Greece, Italy, Czechia, France, Portugal, Denmark, Spain, Poland, Germany, Romania, Belgium, Netherlands
18/09/2026
Phase II
Corvus Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
Italy, Czechia, Germany, Poland, Spain, Bulgaria
18/09/2026
Phase III
Genmab A/S
Neoplasms
Czechia, Netherlands, Lithuania, Ireland, Finland, Hungary, Spain, Greece, Italy, France, Germany, Poland
18/09/2026
Phase III
Ascletis Pharma (China) Co. Ltd.
Nutritional and Metabolic Diseases
Germany, Greece, Czechia, Poland
18/09/2026
Phase III
Ascletis Pharma (China) Co. Ltd.
Nutritional and Metabolic Diseases
Germany, Czechia, Greece, Poland
17/09/2026
Phase III
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Czechia, Greece, France, Italy, Germany, Spain, Poland, Netherlands, Bulgaria
16/09/2026
Phase III
Amgen Inc.
Digestive System Diseases
Belgium, Germany, Hungary, Czechia, Bulgaria, France, Netherlands, Italy, Poland, Greece, Portugal, Spain
16/09/2026
Phase II
Eli Lilly & Co.
Respiratory Tract Diseases
Denmark, France, Romania, Czechia, Poland, Hungary, Germany, Austria
15/09/2026
Phase II
H. Lundbeck A/S
Nervous System Diseases
Czechia, France, Spain, Poland, Italy, Germany, Sweden
15/09/2026
Phase I
Fileclo Sp. z o.o.
Neoplasms
Poland
14/09/2026
Phase II
Enveda Therapeutics Inc.
Skin and Connective Tissue Diseases
Germany, Czechia, Bulgaria, Poland, Spain
10/09/2026
Phase III
Pfizer Inc.
Nutritional and Metabolic Diseases
Spain, France, Germany, Poland, Italy
09/09/2026
Phase II
Kymera Therapeutics Inc.
Immune System Diseases
Austria, Germany, Belgium, Romania, Italy, Slovakia, Poland, Spain
09/09/2026
Phase I
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
2025-523601-16-00Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Foll…
Eli Lilly & Co.
Hemic and Lymphatic Diseases
Spain, Poland, Italy, France, Germany
08/09/2026
Phase III
Amgen Inc.
Neoplasms
Romania, Poland, Germany, Greece, Netherlands, Hungary, Portugal, France, Belgium, Italy, Spain
08/09/2026
Phase IV
Recordati AG
Hormonal diseases
Germany, Bulgaria, France, Romania, Italy, Poland, Spain
08/09/2026
Phase II
Argenx
Immune System Diseases
Germany, Estonia, Lithuania, Portugal, Slovakia, Hungary, Romania, Poland, Spain, Austria, Belgium, France, Bulgaria
08/09/2026
Phase I
AstraZeneca AB
Immune System Diseases
Poland, Hungary
07/09/2026
Phase I
F. Hoffmann-La Roche AG
Neoplasms
Spain, Poland, Romania, Hungary, Germany, Italy, Belgium, Netherlands, Denmark, France
07/09/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, Hungary, Sweden, Lithuania, Croatia, Netherlands, Slovakia, Poland, Austria, Norway, France, Italy, Bulgaria, Spain, Germany, Romania, Slovenia, Estonia, Portugal, Greece, Denmark
02/09/2026
Phase III
Biogen Idec Research Limited
Nervous System Diseases
Portugal, Italy, Belgium, Croatia, Hungary, Germany, Ireland, France, Norway, Poland
31/08/2026
Phase II
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Spain, Hungary, Romania, Slovakia, Poland, Germany
31/08/2026
Phase III
F. Hoffmann-La Roche AG
Neoplasms
France, Spain, Austria, Greece, Portugal, Ireland, Belgium, Italy, Poland, Germany, Netherlands
28/08/2026
Phase II
Contineum Therapeutics Inc.
Respiratory Tract Diseases
Italy, Belgium, Denmark, Austria, Greece, Germany, France, Netherlands, Portugal, Poland, Spain
26/08/2026
Phase II
Pfizer Inc.
Neoplasms
Spain, France, Italy, Ireland, Germany, Poland
26/08/2026
Phase II
Idorsia Pharmaceuticals Ltd.
Skin and Connective Tissue Diseases
Czechia, Poland
26/08/2026
Phase III
UCB Biopharma
Immune System Diseases
Hungary, France, Greece, Poland, Spain, Italy, Germany
25/08/2026
Phase III
Harmony Biosciences Management Inc.
Nervous System Diseases
Belgium, Italy, Germany, France, Spain, Poland
25/08/2026
Phase II
Apollo Therapeutics Limited
Skin and Connective Tissue Diseases
Hungary, Czechia, Germany, Bulgaria, Poland, Spain
25/08/2026
Phase II
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Greece, Hungary, Poland, Belgium, Spain, Netherlands, Germany, France, Portugal, Italy, Romania
25/08/2026
Phase III
Laboratorios Farmaceuticos Rovi S.A.
Neoplasms
Romania, Spain, Bulgaria, Czechia, Latvia, Poland, Croatia, Slovakia
21/08/2026
Phase III
Deciphera Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Austria, Czechia, Italy, Portugal, Germany, France, Hungary, Spain, Poland
21/08/2026
Phase III
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Portugal, Germany, Sweden, Poland, Romania, Finland, Greece, Norway, Spain, Netherlands, France, Hungary
21/08/2026
Phase III
K-Group Beta Inc.
Neoplasms
Germany, Spain, Italy, Belgium, Poland, France, Ireland
21/08/2026
Phase III
Regeneron Pharmaceuticals Inc.
Neoplasms
Italy, Spain, Poland, France, Norway, Greece, Germany
20/08/2026
Phase I/II
Terremoto Biosciences Inc.
Neoplasms
Spain, Ireland, Hungary, Romania, France, Portugal, Belgium, Poland
18/08/2026
Phase III
UCB Biopharma
Immune System Diseases
Hungary, Greece, Italy, Spain, Germany, Poland, France
18/08/2026
Phase II
Ribocure Pharmaceuticals AB
Cardiovascular Diseases
Sweden, Poland
18/08/2026
Phase III
Amgen Inc.
Eye Diseases
Slovakia, Latvia, Czechia, Poland, Spain, Hungary, Lithuania
17/08/2026
Phase III
Pfizer Inc.
Bacterial Infections and Mycoses
Spain, Finland, Poland, Germany, Greece, Hungary, Italy
17/08/2026
Phase III
BioNTech SE
Male Urogenital Diseases
Belgium, Spain, Italy, Poland, Germany, Hungary
17/08/2026
Phase II
Cardurion Pharmaceuticals Inc.
Cardiovascular Diseases
Latvia, Slovakia, Lithuania, Hungary, Italy, Netherlands, Spain, Poland, Bulgaria, Czechia
14/08/2026
Phase III
Narodowe Centrum Badan Jadrowych
Neoplasms
Poland
12/08/2026
Phase II
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Otorhinolaryngologic Diseases
Poland
12/08/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands, Belgium, Greece, Poland, Spain, Denmark, France, Bulgaria, Sweden
10/08/2026
Phase III
Argenx
Hormonal diseases
Italy, Czechia, Spain, Denmark, Belgium, Romania, Latvia, France, Germany, Greece, Sweden, Poland, Lithuania, Bulgaria
07/08/2026
Phase III
AstraZeneca AB
Respiratory Tract Diseases
Denmark, Belgium, France, Italy, Netherlands, Austria, Poland
04/08/2026
Phase II
AstraZeneca AB
Respiratory Tract Diseases
Poland, Hungary, Netherlands, Germany, Spain, Greece, Bulgaria, Italy, France, Denmark
04/08/2026
Phase III
AstraZeneca AB
Nutritional and Metabolic Diseases
Poland, Germany, Bulgaria, Czechia
04/08/2026
Phase I
Sumitomo Pharma America Inc.
Neoplasms
Spain, Bulgaria, Poland, Romania
04/08/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Skin and Connective Tissue Diseases
Denmark, Hungary, Sweden, Netherlands, Germany, Belgium, France, Greece, Norway, Finland, Czechia, Portugal, Bulgaria, Spain, Austria, Romania, Croatia, Poland, Estonia, Italy, Lithuania
03/08/2026
Phase III
Janssen Cilag International
Immune System Diseases
Norway, Romania, Austria, Italy, Slovakia, Germany, Hungary, Netherlands, Belgium, France, Portugal, Czechia, Poland, Spain, Greece
03/08/2026
Phase III
Janssen Cilag International
Immune System Diseases
France, Bulgaria, Romania, Slovakia, Norway, Denmark, Greece, Italy, Austria, Poland, Netherlands, Czechia, Germany, Belgium, Spain, Hungary, Portugal
03/08/2026
Phase IV
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Mental Disorders
Bulgaria, Poland, Hungary
29/07/2026
Phase III
AstraZeneca AB
Cardiovascular Diseases
Spain, Hungary, Germany, Poland, Italy, Bulgaria, Netherlands, Austria, Romania, Sweden, France, Greece, Slovakia, Czechia
29/07/2026
Phase II
Puma Biotechnology Inc.
Neoplasms
France, Poland, Spain
28/07/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Portugal, France, Slovakia, Bulgaria, Netherlands, Romania, Italy, Austria, Poland, Hungary, Spain, Czechia, Belgium
27/07/2026
Phase III
AstraZeneca AB
Nutritional and Metabolic Diseases
Spain, Germany, Italy, Poland
27/07/2026
Phase III
Biogen Idec Research Limited
Nervous System Diseases
Finland, Spain, Italy, Poland, Ireland, Germany, France
24/07/2026
Phase II
Ribocure Pharmaceuticals AB
Cardiovascular Diseases
Norway, Denmark, Poland, Sweden
24/07/2026
Phase III
AstraZeneca AB
Cardiovascular Diseases
Czechia, Italy, Hungary, Romania, Bulgaria, Sweden, Denmark, Poland, Spain, Norway, Finland, Greece, France, Germany
24/07/2026
Phase III
Chemo Research S.L.
Not possible to specify
Sweden, Czechia, Spain, Hungary, Poland, Finland, Romania
23/07/2026
Phase I/II
Bristol-Myers Squibb Services Unlimited Company
Immune System Diseases
Poland, Italy, Spain, Germany
22/07/2026
Phase III
AstraZeneca AB
Nutritional and Metabolic Diseases
Poland, Hungary, Italy, Bulgaria, Germany
22/07/2026
Phase III
Ipsen Bioscience Inc.
Digestive System Diseases
Spain, Sweden, Germany, Romania, Finland, Portugal, Austria, Italy, Denmark, Czechia, France, Netherlands, Poland, Belgium, Norway
21/07/2026
Phase III
Novartis Pharma AG
Nervous System Diseases
Norway, Poland, Spain, Sweden, Bulgaria, Netherlands, Finland, Portugal, Austria, Italy, Greece, Ireland, Czechia, France, Romania, Belgium, Germany, Denmark, Slovakia, Hungary
20/07/2026
Phase III
Alkermes Inc.
Nervous System Diseases
Sweden, Finland, Belgium, Spain, Austria, Netherlands, France, Norway, Germany, Italy, Poland
20/07/2026
Phase III
Arrowhead Pharmaceuticals Inc.
Cardiovascular Diseases
Netherlands, Denmark, Norway, Sweden, Poland
20/07/2026
Phase I
A study comparing the new drugs PG511/PG521/PG531 produced by Celon Pharma SA with the drug PG203 in healthy volunteers.
2025-524936-20-00Treatment of psychotic disorders like schizophrenia Treatme…
Celon Pharma S.A.
Mental Disorders
Poland
20/07/2026
Phase II
Tectonic Operating Company Inc.
Cardiovascular Diseases
Poland, Romania, Spain
17/07/2026
Phase III
Merck Healthcare KGaA
Neoplasms
Belgium, Germany, France, Denmark, Poland, Spain, Netherlands, Italy, Austria
14/07/2026
Phase III
Apellis Pharmaceuticals Inc.
Female Urogenital Diseases and Pregnancy Complications
France, Portugal, Spain, Slovakia, Italy, Germany, Poland
14/07/2026
Phase III
Revolution Medicines Inc.
Digestive System Diseases
Poland, Belgium, Norway, Sweden, Austria, Germany, Denmark, Netherlands, France, Italy, Spain
14/07/2026
Phase II
AstraZeneca AB
Immune System Diseases
France, Germany, Italy, Belgium, Poland, Spain
13/07/2026
Phase I/II
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Germany, Poland, Czechia, Belgium, France, Greece, Sweden, Portugal, Italy
13/07/2026
Phase III
Institut Gustave Roussy
Neoplasms
Sweden, Poland, Denmark, Finland, Netherlands, Italy, France, Spain
08/07/2026
Phase III
Grifols Therapeutics LLC
Nervous System Diseases
Romania, Czechia, Poland
07/07/2026
Phase II
Mediar Therapeutics Inc.
Immune System Diseases
Netherlands, Romania, Poland, France, Italy, Spain
06/07/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Denmark, Sweden, Poland, Estonia, Portugal, Latvia, Spain, Hungary, Germany, Finland, Italy, Belgium, France
06/07/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Germany, Romania, Greece, Norway, Netherlands, Poland, Lithuania, Czechia, Slovakia, Spain
06/07/2026
Phase III
Janssen Cilag International
Neoplasms
Poland, Spain, Czechia, France, Italy, Germany, Greece
01/07/2026
Phase III
Genmab A/S
Neoplasms
Finland, Belgium, Hungary, France, Denmark, Austria, Germany, Italy, Spain, Czechia, Norway, Poland
01/07/2026
Phase III
AstraZeneca AB
Immune System Diseases
Poland, Netherlands, France
30/06/2026
Phase III
Insmed Inc.
Respiratory Tract Diseases
Greece, France, Italy, Belgium, Denmark, Germany, Poland, Czechia, Portugal, Austria, Spain, Romania
30/06/2026
Phase III
Merck Healthcare KGaA
Skin and Connective Tissue Diseases
Germany, Romania, France, Bulgaria, Belgium, Spain, Poland, Greece, Italy, Czechia
29/06/2026
Phase III
Merck Healthcare KGaA
Immune System Diseases
Spain, Belgium, France, Germany, Slovakia, Romania, Bulgaria, Italy, Poland, Greece
29/06/2026
Phase I/II
Revolution Medicines Inc.
Neoplasms
France, Poland, Ireland, Spain, Greece, Germany, Italy, Sweden, Belgium
29/06/2026
Phase III
Incyte Corp.
Neoplasms
Poland, Italy, Netherlands, Sweden, Denmark, Finland, Spain, France, Germany, Belgium, Norway, Austria
26/06/2026
Phase IV
Uniwersytet Medyczny W Lublinie
Hemic and Lymphatic Diseases
Poland
26/06/2026
Phase I
A Phase 1 Study of LBL-051 in Patients with Refractory Autoimmune Disease
2026-525621-20-00B-cell–mediated autoimmune diseases
Oblenio Bio Inc.
Immune system processes
Germany, Romania, Poland
25/06/2026
Phase II
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Poland, Spain, France, Netherlands, Germany
23/06/2026
Phase III
Schneider Children's Medical Center Of Israel
Musculoskeletal Diseases
Greece, Poland, France, Czechia
23/06/2026
Phase II
F. Hoffmann-La Roche AG
Nervous System Diseases
Poland, Germany, France
23/06/2026
Phase III
Adarx Pharmaceuticals Inc.
Immune System Diseases
Poland, Italy, Hungary, France, Austria, Czechia, Belgium, Spain, Bulgaria, Germany, Croatia
22/06/2026
Phase III
Zenas Biopharma (USA) LLC
Nervous System Diseases
Germany, Bulgaria, Netherlands, Sweden, Portugal, Croatia, Italy, Austria, Spain, Poland, France, Denmark, Hungary, Romania, Estonia, Slovakia, Belgium, Czechia, Norway, Lithuania, Greece, Slovenia
22/06/2026
Phase II
Astellas Pharma Global Development Inc.
Neoplasms
Germany, France, Poland, Italy, Spain
22/06/2026
Phase II
Merck Sharp & Dohme LLC
Digestive System Diseases
Italy, Greece, Netherlands, Poland, Germany, France
22/06/2026
Phase I
Pfizer Inc.
Skin and Connective Tissue Diseases
Poland
18/06/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Respiratory Tract Diseases
Finland, Portugal, Hungary, Ireland, Poland, Greece, France, Belgium, Denmark, Italy, Spain, Netherlands, Austria, Germany
17/06/2026
Phase II
Galderma S.A.
Skin and Connective Tissue Diseases
Poland, Italy, Bulgaria, France, Greece, Spain, Croatia
17/06/2026
Phase II
Spyre Therapeutics Inc.
Digestive System Diseases
Croatia, Poland, Austria, Czechia, Italy, Slovakia, Bulgaria, Greece, Belgium, Spain, Hungary, Germany, Lithuania, France, Romania
16/06/2026
Phase III
Glaxosmithkline Research & Development Limited
Nutritional and Metabolic Diseases
Greece, Germany, Belgium, Netherlands, Poland, Italy, France, Spain, Bulgaria, Austria
12/06/2026
Phase II
Eli Lilly & Co.
Digestive System Diseases
Latvia, Portugal, Greece, France, Czechia, Italy, Poland, Slovakia, Hungary, Croatia, Lithuania
10/06/2026
Phase III
Astellas Pharma Global Development Inc.
Neoplasms
Germany, Italy, Spain, Poland, France
10/06/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
France, Spain, Germany, Greece, Italy, Poland
09/06/2026
Phase III
Kardigan Inc.
Cardiovascular Diseases
Norway, Czechia, Portugal, Austria, Poland, France, Spain
08/06/2026
Phase I/II
Merck Sharp & Dohme LLC
Neoplasms
Germany, Poland, Greece, Italy, France, Spain
08/06/2026
Phase III
Zai Lab (US) LLC
Neoplasms
Belgium, Czechia, Germany, Denmark, Greece, Netherlands, Poland, Spain, Austria, Italy, France, Croatia, Romania, Norway
08/06/2026
Phase II
Pfizer Inc.
Respiratory Tract Diseases
Spain, Germany, Poland, Czechia, Greece, Italy, Bulgaria, France, Hungary
08/06/2026
Phase III
Alkermes Inc.
Nervous System Diseases
Spain, Netherlands, Belgium, Italy, France, Austria, Czechia, Germany, Sweden, Poland
04/06/2026
Phase I/II
Nura Bio Inc.
Nervous System Diseases
Poland, Netherlands, Italy, Spain
03/06/2026
Phase III
Alkermes Inc.
Nervous System Diseases
Italy, France, Netherlands, Spain, Belgium, Austria, Czechia, Finland, Germany, Sweden, Norway, Poland
02/06/2026
Phase III
F. Hoffmann-La Roche AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France, Austria, Poland, Netherlands, Spain, Denmark, Italy, Germany, Hungary
01/06/2026
Phase III
F. Hoffmann-La Roche AG
Hemic and Lymphatic Diseases
Hungary, Spain, Ireland, Poland, Austria, Germany, Denmark, Belgium, Netherlands, Italy, France
01/06/2026
Phase III
Innocare Pharma Inc.
Neoplasms
Poland, France, Czechia, Spain, Romania
01/06/2026
Phase III
Novartis Pharma AG
Neoplasms
Belgium, Germany, Austria, Poland, Spain, Italy, Netherlands, Czechia, France
29/05/2026
Phase III
Polska Grupa Badawcza Chloniakow
Neoplasms
Poland
29/05/2026
Phase II
Vertex Pharmaceuticals Inc.
Nervous System Diseases
Poland
29/05/2026
Phase I
Neurocrine Biosciences Inc.
Immune System Diseases
Poland, Romania
29/05/2026
Phase I/II
Uniwersytet Medyczny W Lublinie
Neoplasms
Poland
29/05/2026
Phase I/II
Merck Sharp & Dohme LLC
Neoplasms
Poland, Italy, France, Germany, Spain
28/05/2026
Phase II
F. Hoffmann-La Roche AG
Immune System Phenomena
Italy, Spain, Germany, France, Denmark, Poland, Belgium
27/05/2026
Phase III
Janssen Cilag International
Immune System Diseases
Slovakia, Germany, Denmark, France, Spain, Italy, Netherlands, Belgium, Poland, Sweden, Austria, Czechia, Hungary
27/05/2026
Phase II
Maplight Therapeutics Inc.
Mental Disorders
Italy, Poland, Czechia, Portugal, Bulgaria, France, Slovakia, Romania, Hungary
27/05/2026
Phase II
C4 Therapeutics Inc.
Hemic and Lymphatic Diseases
Italy, France, Spain, Poland
25/05/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
France, Ireland, Germany, Greece, Bulgaria, Spain, Netherlands, Italy, Sweden, Romania, Hungary, Belgium, Austria, Poland
22/05/2026
Phase II
Eikon Therapeutics Inc.
Neoplasms
Germany, Spain, Netherlands, Romania, Greece, Italy, Austria, Belgium, Bulgaria, France, Hungary, Poland
21/05/2026
Phase III
Novartis Pharma AG
Skin and Connective Tissue Diseases
Germany, Spain, France, Poland, Bulgaria, Czechia
20/05/2026
Phase III
Novartis Pharma AG
Immune System Diseases
Portugal, Greece, Germany, Hungary, France, Spain, Bulgaria, Slovakia, Poland, Czechia, Belgium, Italy, Romania, Denmark
20/05/2026
Phase III
Avidity Biosciences Inc.
Musculoskeletal Diseases
Italy, Germany, France, Spain, Belgium, Poland, Netherlands
20/05/2026
Phase I
F. Hoffmann-La Roche AG
Digestive System Diseases
Germany, Poland, Belgium
19/05/2026
Phase III
VarmX B.V.
Hemic and Lymphatic Diseases
Belgium, Germany, Italy, France, Czechia, Bulgaria, Hungary, Spain, Netherlands, Poland, Austria, Estonia, Romania, Portugal, Lithuania
19/05/2026
Phase II
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Nutritional and Metabolic Diseases
Portugal, Greece, Italy, Poland, Estonia, Slovakia, Sweden, Denmark, Belgium, Norway, Romania, France, Spain, Germany, Netherlands, Croatia
19/05/2026
Phase III
Incyte Corp.
Neoplasms
Poland, France, Denmark, Norway, Spain, Germany, Belgium, Netherlands, Austria, Italy
19/05/2026
Phase II
Aimmune Nestle Health Science US R&D LLC
Nutritional and Metabolic Diseases
Poland, Hungary, Spain, Bulgaria, Italy
18/05/2026
Phase III
Zenas Biopharma (USA) LLC
Nervous System Diseases
Italy, Finland, Bulgaria, Greece, Belgium, Estonia, Portugal, Spain, Germany, France, Czechia, Slovakia, Romania, Croatia, Poland, Austria, Netherlands, Denmark, Sweden, Hungary
18/05/2026
Phase II
Novartis Pharma AG
Neoplasms
Spain, France, Germany, Poland, Italy, Netherlands, Greece, Hungary
18/05/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Portugal, Norway, Sweden, Bulgaria, France, Belgium, Austria, Germany, Finland, Poland, Romania, Netherlands, Spain, Italy, Hungary, Czechia
15/05/2026
Phase I/II
Aurinia Pharmaceuticals Inc.
Immune System Diseases
Poland, Spain, Denmark, Latvia, Italy
15/05/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany, Croatia, Portugal, Hungary, Bulgaria, Romania, Poland
15/05/2026
Phase III
Deciphera Pharmaceuticals Inc.
Nervous System Diseases
Czechia, Germany, Italy, Belgium, Spain, Poland, Austria, France, Hungary
14/05/2026
Phase III
Quetzal Therapeutics LLC
Neoplasms
Germany, Poland, Spain, Romania, Italy, France
13/05/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Portugal, Spain, Poland, Sweden, Italy, Czechia, France, Netherlands, Finland, Denmark, Austria, Germany, Belgium, Norway
13/05/2026
Phase II
Innocare Pharma Inc.
Skin and Connective Tissue Diseases
Belgium, Poland, Germany, France, Austria
13/05/2026
Phase III
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Germany, Romania, Czechia, Poland, Hungary, France, Spain, Italy
13/05/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Czechia, Sweden, Poland, Netherlands, Greece, Latvia, Finland, Norway, Belgium, Austria, Portugal, Romania, Italy, Estonia, France, Ireland, Germany, Spain, Bulgaria, Hungary
12/05/2026
Phase III
Takeda Development Center Americas Inc.
Musculoskeletal Diseases
Germany, Belgium, Spain, Czechia, Croatia, Portugal, Poland, Latvia, Bulgaria, France, Estonia, Hungary, Italy
12/05/2026
Phase II
Dualitybio Inc.
Neoplasms
Italy, Poland, France, Spain, Germany
12/05/2026
Phase I
F. Hoffmann-La Roche AG
Nervous System Diseases
Italy, Poland, Denmark, Germany, Portugal, Spain
11/05/2026
Phase III
A. Menarini International Licensing S.A.
Hemic and Lymphatic Diseases
Spain, Poland, Netherlands, Italy, Slovakia, Czechia, Germany
11/05/2026
Phase III
Octapharma Pharmazeutika Produktionsgesellschaft mbH
Immune System Diseases
Czechia, Lithuania, Greece, Poland, Germany, Latvia, Bulgaria, Italy
11/05/2026
Phase III
Eli Lilly & Co.
Neoplasms
Netherlands, Hungary, France, Austria, Poland, Italy, Denmark, Romania, Greece, Norway, Czechia, Belgium, Spain, Ireland, Germany
11/05/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Germany, Netherlands, Portugal, Denmark, Sweden, Finland, France, Spain, Austria, Italy, Hungary, Romania, Belgium, Czechia, Poland
11/05/2026
Phase III
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Poland, Hungary, France, Belgium, Italy, Netherlands, Czechia, Germany, Spain
07/05/2026
Phase I
PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION
2025-523641-10-00Healthy / hepatic impaired volunteers only study to assess …
Zealand Pharma A/S
Not possible to specify
Slovakia, Poland
06/05/2026
Phase I
Amgen Inc.
Neoplasms
Spain, Germany, Poland, Belgium, France
05/05/2026
Phase III
Dompe' Farmaceutici S.p.A.
Eye Diseases
Czechia, Italy, Netherlands, Poland, Germany, Spain, Hungary, France
05/05/2026
Phase II
Immunovant Sciences GmbH
Immune System Diseases
Italy, Greece, Germany, Hungary, Poland, Czechia, Netherlands, Spain, Belgium, Bulgaria, Latvia
05/05/2026
Phase III
Biomarin Pharmaceutical Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Poland, Italy, Romania, France, Norway, Netherlands, Sweden
05/05/2026
Phase III
Janssen Cilag International
Immune System Diseases
Denmark, Hungary, Portugal, Italy, Norway, Greece, Slovakia, Czechia, France, Poland, Bulgaria, Germany, Spain, Romania, Finland
05/05/2026
Phase II
Novartis Pharma AG
Eye Diseases
Bulgaria, Romania, Germany, Czechia, Spain, Poland, Italy, Hungary, France
04/05/2026
Phase III
Kailera Therapeutics Inc.
Nutritional and Metabolic Diseases
Hungary, Poland, Bulgaria, Germany, Czechia, Spain
04/05/2026
Phase II
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Immune System Diseases
Bulgaria, Romania, Germany, Spain, Hungary, Poland, Croatia, Netherlands
04/05/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Denmark, Spain, Netherlands, Germany, France, Czechia, Poland, Italy, Greece
04/05/2026
Phase I
Regeneron Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
Belgium, Czechia, Germany, Poland
30/04/2026
Phase II
Merck Sharp & Dohme LLC
Musculoskeletal Diseases
Poland, Germany, Spain
30/04/2026
Phase I
Bioresearch Pharma S.A.
Skin and Connective Tissue Diseases
Poland
29/04/2026
Phase III
Inhibikase Therapeutics Inc.
Cardiovascular Diseases
Spain, Poland, Italy, Belgium, Latvia, Denmark, Czechia, Germany, France, Netherlands, Portugal, Ireland, Austria, Greece, Lithuania
28/04/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Czechia, Spain, Poland, Belgium, Finland, Germany, France, Netherlands, Hungary, Denmark
28/04/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Slovakia, Austria, Spain, Romania, Portugal, Italy, Denmark, Belgium, Sweden, Poland, Netherlands, Croatia, Hungary, Bulgaria
28/04/2026
Phase III
Epygenix Therapeutics Inc.
Nervous System Diseases
Italy, Spain, Hungary, Romania, Czechia, Poland
28/04/2026
Phase III
Exciva GmbH
Nervous System Diseases
Italy, Slovakia, Spain, Poland, Czechia, Germany
28/04/2026
Phase II
Chiesi Farmaceutici S.p.A.
Respiratory Tract Diseases
Belgium, Germany, Italy, Czechia, Bulgaria, Netherlands, France, Portugal, Poland, Spain, Romania
27/04/2026
Phase III
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Belgium, Czechia, France, Romania, Germany, Poland, Bulgaria, Spain
27/04/2026
Phase IV
Eli Lilly & Co.
Immune System Diseases
Spain, Denmark, Germany, Italy, Poland
27/04/2026
Phase II
AstraZeneca AB
Neoplasms
Italy, Austria, Spain, Ireland, Czechia, Poland
27/04/2026
Phase I/II
Fortvita Biologics (USA) Inc.
Respiratory Tract Diseases
Poland, Denmark, Spain
27/04/2026
Phase IV
Lallemand Pharma Europe filial af Lallemand Pharma AG Schweiz
Respiratory Tract Diseases
Poland
23/04/2026
Phase I
Instytut Pomnik Centrum Zdrowia Dziecka
Nervous System Diseases
Poland
23/04/2026
Phase II
AstraZeneca AB
Immune System Diseases
Hungary, Spain, Bulgaria, Germany, Poland
22/04/2026
Phase II
Corxel Pharmaceuticals Inc.
Nutritional and Metabolic Diseases
Poland
22/04/2026
Phase I/II
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Poland, Spain, Germany, France, Italy
22/04/2026
Phase III
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Not possible to specify
France, Romania, Poland, Spain, Bulgaria
21/04/2026
Phase II
Novo Nordisk A/S
Hormonal diseases
Spain, Hungary, Portugal, Poland, Slovakia, Croatia
21/04/2026
Phase III
BeOne Medicines I GmbH
Neoplasms
Netherlands, Poland, Italy, Germany, Spain, Romania, Czechia, France, Sweden
20/04/2026
Phase II
CSL Behring LLC
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Austria, Poland, Spain, Germany, France, Ireland, Romania, Belgium, Italy, Czechia, Netherlands
20/04/2026
Phase II
Instytut Matki I Dziecka
Neoplasms
Poland
20/04/2026
Phase III
Ferrer Internacional S.A., Prilenia Therapeutics B.V.
Nervous System Diseases
Belgium, Netherlands, Poland, France, Germany, Ireland, Italy, Sweden, Spain
20/04/2026
Phase III
Incyte Corp.
Neoplasms
Ireland, Poland, France, Netherlands, Spain, Italy, Germany, Belgium
17/04/2026
Phase III
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Greece, Bulgaria, Italy, Netherlands, Spain, Poland, Czechia, Germany, France
17/04/2026
Phase III
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
France, Belgium, Germany, Italy, Bulgaria, Ireland, Lithuania, Norway, Romania, Hungary, Spain, Greece, Poland, Netherlands
17/04/2026
Phase III
Metsera Inc.
Nutritional and Metabolic Diseases
Czechia, Bulgaria, Slovakia, Spain, Hungary, Germany, Romania, Poland
16/04/2026
Phase III
Guerbet, Bracco Imaging S.p.A.
Cardiovascular Diseases
Italy, France, Czechia, Hungary, Spain, Germany, Poland
15/04/2026
Phase III
UCB Biosciences Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Poland, France, Hungary, Belgium, Italy, Germany
15/04/2026
Phase II
Genmab A/S
Neoplasms
Germany, Hungary, Netherlands, France, Italy, Belgium, Spain, Poland
14/04/2026
Phase II
Pfizer Inc.
Skin and Connective Tissue Diseases
Poland, Czechia, Germany, Bulgaria, France
14/04/2026
Phase II
Enlivex Therapeutics Ltd.
Musculoskeletal Diseases
Denmark, Poland
13/04/2026
Phase III
Praxis Precision Medicines Inc.
Nervous System Diseases
Poland, Germany, Czechia, Italy, Spain
10/04/2026
Phase II
Kymera Therapeutics Inc.
Immune System Diseases
Spain, Romania, Slovakia, Poland, Germany, Italy, Belgium, Austria
10/04/2026
Phase II
Merus B.V.
Not possible to specify
Spain, Belgium, Netherlands, Poland, Italy, France
09/04/2026
Phase III
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Germany, Belgium, Netherlands, Denmark, Spain, Greece, Poland, Hungary, France, Italy, Bulgaria, Romania
07/04/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Italy, Greece, Spain, Bulgaria, Denmark, Poland
07/04/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Poland, Spain, Bulgaria, Italy, Denmark
07/04/2026
Phase III
Alfasigma S.p.A.
Musculoskeletal Diseases
Spain, Bulgaria, France, Belgium, Germany, Greece, Italy, Poland, Hungary, Czechia
07/04/2026
Phase I
Agios Pharmaceuticals Inc.
Nutritional and Metabolic Diseases
Poland
03/04/2026
Phase II
Askbio Inc.
Nervous System Diseases
Poland
03/04/2026
Phase III
Metsera Inc.
Nutritional and Metabolic Diseases
Germany, Hungary, Slovakia, Poland, Spain, Czechia, Romania, Bulgaria
02/04/2026
Phase III
Alfasigma S.p.A.
Immune System Diseases
France, Germany, Poland, Belgium, Hungary, Spain, Czechia, Greece, Italy
01/04/2026
Phase II
Almirall S.A.
Skin and Connective Tissue Diseases
Bulgaria, Spain, France, Poland, Germany
01/04/2026
Phase II
Bluefin Biomedicine Inc.
Immune System Diseases
Spain, Germany, Czechia, Poland, Bulgaria
31/03/2026
Phase I/II
AstraZeneca AB
Neoplasms
Germany, Spain, France, Poland, Belgium, Netherlands, Italy
30/03/2026
Phase IV
Fakultni Nemocnice V Motole
Nervous System Diseases
Czechia, Poland
30/03/2026
Phase III
Xenon Pharmaceuticals Inc.
Mental Disorders
Finland, Poland, Romania, Slovakia, Spain, Germany
30/03/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Denmark, Poland, Spain, Germany
30/03/2026
Phase I
AstraZeneca AB
Neoplasms
Poland
27/03/2026
Phase III
Genmab A/S
Neoplasms
Poland, Denmark, Finland, Lithuania, France, Germany, Spain, Belgium, Greece, Norway, Italy
26/03/2026
Phase II
Navigator Medicines Inc.
Skin and Connective Tissue Diseases
Hungary, Poland, Germany, Bulgaria, Romania
25/03/2026
Phase III
Celldex Therapeutics Inc.
Skin and Connective Tissue Diseases
Germany, Lithuania, Spain, Poland
25/03/2026
Phase II
Shanghai Henlius Biotech Inc.
Therapeutics
Italy, Romania, Poland, Spain, France
25/03/2026
Phase II
Almirall S.A.
Skin and Connective Tissue Diseases
Bulgaria, Romania, Poland, Germany, Spain
24/03/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Poland, Spain, Germany
24/03/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Germany, Spain, Poland, Czechia, Slovakia
24/03/2026
Phase III
Tenax Therapeutics Inc.
Cardiovascular Diseases
France, Italy, Germany, Czechia, Austria, Poland, Hungary, Bulgaria, Spain
24/03/2026
Phase III
Pfizer Inc.
Neoplasms
France, Italy, Hungary, Greece, Czechia, Spain, Poland, Germany
24/03/2026
Phase I
Glaxosmithkline Research & Development Limited
Immune System Diseases
Germany, France, Italy, Spain, Poland
23/03/2026
Phase II
Janssen Cilag International
Immune System Diseases
Spain, Poland, Czechia, Germany, Hungary
20/03/2026
Phase II
Kiniksa Pharmaceuticals GmbH
Therapeutics
Spain, Greece, Germany, France, Italy, Poland
19/03/2026
Phase II
Eli Lilly & Co.
Digestive System Diseases
Hungary, Spain, Denmark, Netherlands, Poland, Romania, Germany, Italy, Austria
18/03/2026
Phase II
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Latvia, Belgium, France, Poland, Germany, Spain, Czechia
18/03/2026
Phase III
Pharvaris Netherlands B.V.
Immune System Diseases
Hungary, Spain, Austria, Germany, Poland, Netherlands, France, Italy, Bulgaria
17/03/2026
Phase I/II
Medilink Therapeutics (Suzhou) Co. Ltd.
Neoplasms
Poland, Spain, France, Romania, Italy, Belgium, Hungary, Germany
17/03/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Male Urogenital Diseases
Germany, Croatia, Poland, Sweden, Portugal, Netherlands, Italy, Denmark, Slovakia, Spain, Norway, Romania, Belgium, Greece, France
17/03/2026
Phase III
Celldex Therapeutics Inc.
Skin and Connective Tissue Diseases
Croatia, France, Netherlands, Bulgaria, Portugal, Slovakia, Hungary, Italy, Greece, Germany, Czechia, Lithuania, Spain, Belgium, Denmark, Poland
16/03/2026
Phase I
UCB Biopharma
Immune System Diseases
Croatia, Poland, Germany, Czechia, Slovakia, Bulgaria
16/03/2026
Phase IV
Care Arthritis Ltd.
Eye Diseases
Spain, Poland, Netherlands, France, Bulgaria, Germany
13/03/2026
Phase II
Zydus Therapeutics Inc.
Nervous System Diseases
Spain, Germany, Sweden, Ireland, Poland, Italy, Belgium, France, Netherlands
12/03/2026
Phase III
Liquidia Technologies Inc.
Respiratory Tract Diseases
Latvia, Germany, Italy, Czechia, France, Belgium, Portugal, Poland, Austria, Spain
11/03/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Germany, Spain, Poland, France, Italy, Romania
10/03/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Sweden, Czechia, Belgium, Romania, Netherlands, Italy, France, Spain, Germany, Poland, Austria
10/03/2026
Phase III
Xenon Pharmaceuticals Inc.
Mental Disorders
Germany, Bulgaria, Spain, Poland
10/03/2026
Phase II
AbbVie Deutschland GmbH & Co. KG
Respiratory Tract Diseases
Greece, Italy, Sweden, Germany, Portugal, Spain, France, Hungary, Poland, Bulgaria, Romania
10/03/2026
Phase III
Ionis Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Italy, Germany, Poland, Spain
09/03/2026
Phase II
Takeda Development Center Americas Inc.
Skin and Connective Tissue Diseases
France, Poland, Netherlands, Germany
06/03/2026
Phase II
Sanofi-Aventis Recherche & Developpement
Digestive System Diseases
Belgium, Germany, Czechia, Netherlands, Spain, Austria, Italy, Greece, Croatia, Bulgaria, Poland, France, Romania, Hungary
06/03/2026
Phase III
Alvotech Swiss AG
Eye Diseases
Latvia, Slovakia, Czechia, Hungary, Poland, Bulgaria
06/03/2026
Phase III
Novartis Pharma AG
Nervous System Diseases
Denmark, Slovenia, Netherlands, Portugal, Ireland, Sweden, Croatia, Greece, Germany, Latvia, Czechia, Spain, Romania, Belgium, Austria, Lithuania, Slovakia, Poland, Estonia, Bulgaria, France, Italy, Hungary, Finland, Norway
03/03/2026
Phase II
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Poland, Italy, Belgium, Sweden, Hungary, France, Germany, Spain, Denmark
02/03/2026
Phase II
Pfizer Inc.
Digestive System Diseases
Finland, Poland, France, Germany, Italy, Slovakia
27/02/2026
Phase III
AstraZeneca AB
Neoplasms
Spain, Poland, Hungary, Italy, Germany, France, Belgium, Austria
26/02/2026
Phase III
Ionis Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Italy, Spain, Poland
25/02/2026
Phase III
MoonLake Immunotherapeutics AG
Musculoskeletal Diseases
Estonia, Croatia, Slovakia, Lithuania, Romania, Hungary, Germany, France, Latvia, Poland, Portugal, Greece, Czechia, Bulgaria, Finland, Spain
25/02/2026
Phase II
Draig Therapeutics Limited
Mental Disorders
Czechia, Bulgaria, Poland
24/02/2026
Phase III
Eli Lilly & Co.
Cardiovascular Diseases
Germany, Czechia, Lithuania, Spain, Austria, France, Hungary, Greece, Estonia, Netherlands, Slovakia, Poland, Romania, Bulgaria, Italy, Belgium
24/02/2026
Phase II
Merck Sharp & Dohme LLC
Neoplasms
Italy, Poland, Spain, Finland, Netherlands, Greece
24/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Spain, Czechia, Lithuania, Hungary, Greece, Bulgaria, Poland, Belgium, France, Germany, Norway, Austria, Netherlands, Italy, Slovakia
24/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Netherlands, Poland, Greece, Czechia, Italy, Bulgaria, Belgium, Germany, Lithuania, Austria, Spain, Hungary, Norway, France
24/02/2026
Phase III
Amgen Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Germany, Hungary, Italy, Belgium, Austria, Slovakia, Spain, Poland
23/02/2026
Phase III
Kura Oncology Inc.
Neoplasms
Belgium, Spain, Italy, Czechia, Hungary, Poland, France, Portugal, Germany, Greece
20/02/2026
Phase III
Eli Lilly & Co.
Cardiovascular Diseases
Slovakia, Poland, France, Netherlands
17/02/2026
Phase III
Olema Pharmaceuticals Inc.
Neoplasms
Hungary, Portugal, Italy, France, Poland, Czechia, Germany, Spain, Belgium, Austria, Romania, Greece, Netherlands
17/02/2026
Phase III
Novartis Pharma AG
Cardiovascular Diseases
Germany, Hungary, Poland, France, Spain
16/02/2026
Phase II
Pediatric Research International GmbH
Neoplasms
Denmark, Italy, Czechia, Sweden, Poland, Netherlands, Germany, Austria
16/02/2026
Phase I
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, France, Hungary, Poland, Spain, Bulgaria
16/02/2026
Phase III
CatalYm GmbH
Nutritional and Metabolic Diseases
France, Czechia, Romania, Italy, Germany, Poland, Spain, Bulgaria, Norway, Ireland, Netherlands
13/02/2026
Phase III
Syndax Pharmaceuticals Inc.
Neoplasms
Greece, Poland, Spain, Austria, Italy, Romania, Belgium, France, Lithuania, Germany, Hungary, Czechia, Portugal
13/02/2026
Phase III
Regeneron Pharmaceuticals Inc.
Neoplasms
Greece, Spain, Poland, Italy, Austria, Czechia, Belgium, Germany, Netherlands, France
10/02/2026
Phase III
Amgen Inc.
Respiratory Tract Diseases
Poland, Germany, Czechia, Hungary, Spain, France
10/02/2026
Phase III
Argenx
Nervous System Diseases
Czechia, Denmark, Poland, Slovenia, Netherlands, Austria, Estonia, Slovakia, Hungary, Finland, Bulgaria, France, Italy, Greece, Romania
10/02/2026
Phase IV
Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
2025-521621-33-00Hepatocellular Carcinoma, Metastatic Melanoma, Melanoma, Ad…
Replimune Group Inc.
Neoplasms
Germany, Greece, France, Poland, Spain
09/02/2026
Phase III
Astria Therapeutics Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Netherlands, Spain, Poland, Germany, Czechia, Austria, Portugal, Hungary, France, Italy, Bulgaria
09/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Germany, Austria, Italy, Czechia, Netherlands, Poland, Belgium, Hungary, Lithuania, Greece, France, Bulgaria, Spain, Norway
09/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Austria, France, Norway, Hungary, Bulgaria, Netherlands, Czechia, Slovakia, Germany, Lithuania, Greece, Belgium, Italy, Spain, Poland
09/02/2026
Phase II
GSK PLC
Respiratory Tract Diseases
Denmark, France, Spain, Italy, Germany, Poland
09/02/2026
Phase III
Glaxosmithkline Research & Development Limited
Neoplasms
France, Romania, Spain, Netherlands, Norway, Belgium, Hungary, Italy, Poland, Germany
06/02/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Finland, Germany, Italy, France, Sweden, Poland, Spain, Belgium, Czechia, Netherlands, Portugal, Norway
03/02/2026
Phase III
Alnylam Pharmaceuticals Inc.
Cardiovascular Diseases
Belgium, Hungary, Czechia, Austria, Germany, France, Greece, Spain, Romania, Netherlands, Italy, Poland, Slovakia, Sweden, Portugal, Denmark, Bulgaria
03/02/2026
Phase II
Sab Biotherapeutics Inc.
Nutritional and Metabolic Diseases
Austria, Germany, Poland, Italy, Denmark, Spain, Belgium, Finland, France, Lithuania, Slovenia
02/02/2026
Phase III
Kardigan Inc.
Cardiovascular Diseases
Spain, Denmark, Belgium, Hungary, Italy, Poland, France, Sweden, Netherlands
30/01/2026
Phase I
Lifordi Immunotherapeutics Inc.
Immune System Diseases
Poland
30/01/2026
Phase III
Ideaya Biosciences Inc.
Eye Diseases
France, Spain, Poland, Italy, Czechia, Belgium, Austria, Netherlands, Denmark, Germany, Slovenia
29/01/2026
Phase II
F. Hoffmann-La Roche AG
Nervous System Diseases
Germany, Spain, France, Hungary, Italy, Poland, Portugal
28/01/2026
Phase III
Amgen Inc.
Respiratory Tract Diseases
Poland, Czechia, Germany, Hungary, France, Spain
27/01/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Czechia, France, Netherlands, Bulgaria, Norway, Austria, Poland, Spain, Italy, Hungary, Germany, Romania, Sweden, Portugal, Belgium
27/01/2026
Phase III
Insmed Inc.
Respiratory Tract Diseases
Portugal, Italy, Czechia, Poland, Denmark, Greece, Germany, Romania, Spain, France, Belgium, Austria
26/01/2026
Phase III
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Germany, Spain, Belgium, Czechia, Norway, France, Poland, Netherlands, Italy, Finland
26/01/2026
Rows per page Showing 1–500 of 620
1 2 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 November 2026. https://priyalifescience.com/clinical-trials-europe/country/poland

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,893 trial records at the last sync on 20 Nov 2026, 03:17 UTC; this register shows the 2,556 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 620 of those trials with a site in Poland.

How many recently authorised EU trials have a site in Poland?

620 of the 2,556 most recently authorised trials in this register list a site in Poland; 356 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase (Poland), 620 trials
PhaseTrialsShare
Phase III35657.4%
Phase II17828.7%
Phase I396.3%
Phase I/II335.3%
Phase IV142.3%

Most active sponsors

Lead sponsors with the most trials (Poland)
Lead sponsorTrials
AstraZeneca AB38
F. Hoffmann-La Roche AG25
Eli Lilly & Co.23
Merck Sharp & Dohme LLC23
Novo Nordisk A/S18
Novartis Pharma AG17
Pfizer Inc.17
Sanofi-Aventis Recherche & Developpement16
Bristol-Myers Squibb Services Unlimited Company15
Glaxosmithkline Research & Development Limited14
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.